Conference Accreditation
Taming the Flames: Inflammation in Cardiometabolic Disease
ACTIVITY TITLE
Taming the Flames: Inflammation in Cardiometabolic Disease
ACTIVITY DATE
May 19-20, 2023 at the Gaylord Palms, Orlando, FL
TARGET AUDIENCE
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Discuss the interrelationships among inflammation & cardiometabolic risk factors, as well as the role of inflammation on the development of cardiometabolic diseases, including diabetes, dyslipidemia, hypertension, obesity, kidney disease, and cardiovascular disease.
- Interpret the latest evidence and guidelines for the prevention, screening, and treatment of the complex patient with cardiometabolic risk or cardiometabolic disease.
- Outline strategies aimed at timely screening and prevention of cardiometabolic disease, including assessment of risk factors and biomarkers, and lifestyle modifications.
- Develop individualized treatment regimens for patients with cardiometabolic disease based on the efficacy and safety of current and new pharmacotherapies, patient comorbidities and preferences in order to optimize outcomes.
- Summarize recent evidence for emerging therapies in order to stay current with the most recent updates in the cardiometabolic field.
Â
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of 9.25 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 9.25 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 9.25 contact hour(s) (0.925 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008073-9999-23-145-L01-P. Type of activity: Application
DIETITIAN CONTINUING EDUCATION
This program offers 9.25 CPEUs for dietitians.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is a registration fee for participating and receiving CME/CE credit for this educational activity. Registration information can be found here.
HOW TO REQUEST CE CREDIT
Learners may earn up to a maximum of 9.25 AMA/ACPE/ANCC/CDR credits for attending the meeting. An evaluation link will be emailed to attendees after the meeting on Saturday, May 20. Learners must complete the evaluation by Wednesday, May 31, 2023. Upon completion of the CME/CE evaluation, attendees can download their Session 5 certificate. Several email reminders with this link will be sent the next week.
For Pharmacists: Pharmacists have until the May 31 deadline to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Expect credit uploads to be completed within 5-7 business days after the evaluation deadline. For questions regarding the evaluation, please contact: cmhc_eval@ cardiometabolichealth.org.
DISCLOSURES
Information on planner and faculty disclosures can be found here.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
